Sunday, September 7, 2014

First of its kind Biomarker test which detect early onset of Acute Kidney Injury

First of its kind Biomarker test which detect early onset of Acute Kidney Injury.

Early intervention and prediction of onset of kidney failure or injury is very important in initiation of treatment of patient affected with kidney diseases. US FDA approved new biomarker test which find out presence of insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) in the urine with in 20 minutes.

Insulin-like growth-factor binding protein 7 (IGFBP7) and tissue inhibitor of metalloproteinases (TIMP-2) are associated with kidney injury and its early detection of their presence will help in predicting likeness of Acute Kidney Injury and help in deciding line of treatment.

NephroCheck is the diagnostic test which is a first of its kind test approved by US FDA. FDA have approved this test under De novo premarket approval which promote novel drugs and medicines, medical devices which are prove life saving and event there is no such existing device or drug previously approved for indicated use by US FDA.

NephroCheck is manufactured by California based Astute Medical.

You May Like :
New kidney function test which can precisely predict early onset of kidney failure


New biomarker identified which is linked to increased risk of kidney failure.

Posted by: Martin

How to sucessfuly activate and receive our articles on pharmaceuticals by E-Mail

Dear readers if you wish to receive our articles on pharmaceutical automatically into your email Inbox , as and when we write a new article over this website, then follow these 3 simple steps.


1.You should write your Email ID in the box provided and push the subscribe butten


2.Enter the text code that we show you in a small new browser window after you enter your email ID.

3.Log in to your email and Cheke our verification email sent by "FEEDBURNER" , there you should verify the link we send you by email.




Enter your email address get our articles by email whenever this website is updated





Delivered by FeedBurner



Join the list of our readers from Universities ,Research and Development centers Pharmaceutical Companies from all over the world.











Pharma Research Regulatory Guidelines Website
Texas Dallas, TX 75211 US
Email: editor@pharmacistspharmajournal.org Website: http://pharmacistspharmajournal.org/
Copyright © 2008-2014 all rights reserve www.pharmacistspharmajournal.org